Clinical trials: Nonsquamous Non-small Cell Lung Cancer
Lung Cancer Non-small Cell Stage IV
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
This is a phase III , randomized, double-blinded, multicenter clinical study to compare efficacy and safety of AK105 (Anti-PD1 antibody) combined with Carboplatin and Pemetrexed vs Placebo combined with Carboplatin and Pemetrexed…
- Trial name
- NCT03866980
- Testing
- AK105, carboplatin, pemetrexed
- Where
- 2 sites in China
- Volunteers
- 164 people
- Sponsor
- Akeso
Non-small Cell Lung Cancer
Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC
Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit…
- Trial name
- NCT03654027
- Testing
- Anlotinib Plus Docetaxel, Docetaxel
- Volunteers
- 84 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
NSCLC, Non Small Cell Lung Cancer
Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer
The goal of this clinical study is to learn more about the study drug TUB-040, safety, tolerability, pharmacokinetics (PK), and effectiveness in treating patients with unresectable or metastatic non-small cell lung cancer…
- Trial name
- NCT07806773
- Testing
- TUB-040
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Gilead Sciences
Medical Oncology
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Determine the safety, tolerability and maximum tolerated dose of anetumab ravtansine (BAY 94-9343) in combination with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 in subjects with mesothelin-expressing predominantly epithelial…
- Trial name
- NCT02639091
- Testing
- BAY 94-9343, Pemetrexed, Cisplatin
- Where
- 6 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum…
- Trial name
- NCT05920356
- Testing
- Sotorasib, Pembrolizumab
- Where
- 424 sites in United States, Argentina and 36 more
- Volunteers
- 750 people
- Sponsor
- Amgen
Lung Adenocarcinoma, Neutropenia
Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy
Folic acid (FA; folate) in the dose of 350-1,000 μg daily should be supplemented, daily, starting 7 days before the first dose of pemetrexed based chemotherapy and should be continued while the patient is on therapy and for 21…
- Conditions
- Lung Adenocarcinoma, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- PEMVITASTART (NCT02679443)
- Testing
- Folate and B12
- Where
- India
- Volunteers
- 161 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer
This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab…
- Conditions
- Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03793179
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 1,094 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
To investigate efficacy and safety of the combination with pemetrexed plus carboplatin, followed by pemetrexed in patients with advanced nonsquamous Non Small Cell Lung Cancer (NSCLC) who receive at least one dose of the…
- Trial name
- NCT01020786
- Testing
- Pemetrexed, Carboplatin
- Where
- 16 sites in Japan
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung…
- Trial name
- NCT06305754
- Testing
- Sacituzumab tirumotecan, Pemetrexed, Carboplatin
- Where
- 156 sites in United States, Argentina and 17 more
- Volunteers
- 550 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer, Brain Metastases
Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases
The purpose of this study was to investigate the efficacy and safety of Cadonilimab combined with bevacizumab and chemotherapy for advanced non-squamous NSCLC with untreated brain metastases.
- Trial name
- CBC (NCT05812534)
- Testing
- Cadonilimab
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)
The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic…
- Trial name
- NCT03829319
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 158 sites in United States, Argentina and 15 more
- Volunteers
- 761 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
The study will first determine the optimal dose of inupadenant to be given in combination with carboplatin and pemetrexed to patients that progressed after receiving first line anti-PD(L)1 treatment for locally advanced or…
- Trial name
- NCT05403385
- Testing
- inupadenant, Carboplatin, Pemetrexed
- Where
- 21 sites in United States, Belgium and 6 more
- Volunteers
- 36 people
- Sponsor
- iTeos Therapeutics
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
- Trial name
- POD1UM-304 (NCT04205812)
- Testing
- Retifanlimab, Pemetrexed, Cisplatin
- Where
- 140 sites in United States, Brazil and 15 more
- Volunteers
- 583 people
- Sponsor
- Incyte Corporation
Non-squamous Cell Non-Small Cell Lung Cancer
Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC
In recent years, with the progress in the treatment field, NSCLC has become the most successful cancer species in precision medicine.
- Trial name
- ALTER-L025 (NCT03778138)
- Testing
- Anlotinib plus Pemetrexed
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Henan Provincial People's Hospital
Advanced Non-squamous Non-small-cell Lung Cancer
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC
This is a double-blind Phase 3 clinical trial evaluating the efficacy and safety of TRS003 and paclitaxel-carboplatin versus China-approved bevacizumab and paclitaxel-carboplatin in patients with unresectable, locally advanced…
- Trial name
- NSCLC (NCT04416035)
- Testing
- TRS003, China-approved Bevacizumab, Carboplatin
- Where
- 11 sites in China
- Volunteers
- 608 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Carcinoma, Non-Small-Cell Lung
Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer
The purpose of this trial is to estimate the therapeutic efficacy of the experimental targeted regimen including the EGFR antibody panitumumab (in combination with pemetrexed and cisplatin) in relation to the standard combination…
- Trial name
- NCT01088620
- Testing
- Panitumumab, Pemetrexed, Cisplatin
- Where
- 20 sites in Germany
- Volunteers
- 134 people
- Sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic
A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
The main purpose for this study is to answer the following research questions: Can pemetrexed be administered safely at the participant's home, using the same treatment procedure as in a hospital setting? Will the participant be…
- Conditions
- Nonsquamous Non-Small Cell Neoplasm of Lung, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer Stage IIIB
- Trial name
- NCT01473563
- Testing
- Pemetrexed
- Where
- 9 sites in Sweden, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer
The purpose of this trial is to assess how well the combination of pemetrexed with cisplatin can reduce tumor size.
- Trial name
- NCT01165021
- Testing
- Pemetrexed, Cisplatin, Folic Acid
- Where
- 7 sites in Italy
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Nonsquamous Nonsmall Cell Neoplasm of Lung
Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab
This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.
- Trial name
- ANGIOMET (NCT01814163)
- Testing
- paclitaxel, carboplatin and bevacizumab
- Where
- 20 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Spanish Lung Cancer Group
Carcinoma, Non-Small-Cell Lung
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT06780085
- Testing
- Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel
- Where
- 35 sites in United States, Chile and 8 more
- Volunteers
- 96 people
- Sponsor
- Merck Sharp & Dohme LLC